QRxPharma Inc.
7
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.5% vs industry average
71%
5 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Double Blind Efficacy and Safety Study of Flexible-Dose vs Low-Dose Q8003 After Undergoing Primary Unilateral Total Knee Arthroplasty
Role: lead
Comparison of the Safety of Q8003 Versus Morphine Equivalent Doses of Its Components (Oxycodone and Morphine) in Bunionectomy Patients
Role: lead
Pilot Study of the Efficacy and Safety of Q8003 in Patients Who Have Undergone Total Knee Arthroplasty or Total Hip Arthroplasty
Role: lead
Efficacy and Safety of Q8003 in the Management of Post-bunionectomy Pain
Role: lead
Extension Study to Evaluate the Safety of Q8003 in Patients With Acute Moderate to Severe Pain
Role: lead
Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients
Role: lead
Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients
Role: lead
All 7 trials loaded